Navigation Links
Wellmune WGP supplementation alleviates
Date:4/8/2008

SAN DIEGO, CA. April 9, 2008 Wellmune WGP, a natural immune-enhancing ingredient from Biothera, reduced the incidence of fever and eliminated the need for study subjects to miss work or school due to the cold-like symptoms, researchers reported today at the 2008 Experimental Biology annual meeting.

Don Cox, Ph.D., Vice President of Research & Development for Biotheras Healthcare Group, said, This studys results are exciting because they show the potential for Wellmune WGP to naturally enhance the bodys innate immune response to protect against and ameliorate the symptoms of something that every one of us encountersthe common cold. These results are consistent with numerous other immune health studies conducted with our ingredient, and indicate the real-life benefits that Wellmune WGP supplementation can provide.

The research will be presented at the Poster Sessions starting 9:00 am on April 9th by Douglas Kalman, Ph.D., RD, FACN, a Director at Miami Research Associates, which conducted the study for Biothera. An abstract of the study is available at www.biothera.com/healthcare.

The double-blind, placebo-controlled study was conducted during the cold season with 40 healthy subjects, aged 18-65. The subjects were treated daily with either 250mg of Wellmune WGP or a placebo for 90 days. Wellmune WGP is a natural carbohydrate that activates key immune cells, including macrophages and neutrophils, to more quickly recognize and kill foreign challenges. The product engages the bodys natural defenses to promote health, wellness and vitality. In contrast with the placebo group, study participants who received Wellmune WGP daily reported:

  • No incidence of medically verified fever.

  • An increase in general health markers, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2).

  • No
    '/>"/>

Contact: Dave Walsh
651-256-4606
Strategic Communications
Source:Eurekalert

0

GOOD

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4